Cue Biopharma logo

Cue BiopharmaNASDAQ: CUE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 January 2018

Next earnings report:

08 April 2025

Last dividends:

N/A

Next dividends:

N/A
$66.52 M
-85%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-64%vs. 3y high
65%vs. sector
-98%vs. 3y high
69%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:42:45 GMT
$1.05-$0.03(-2.78%)

Dividend

No data over the past 3 years
$3.34 M$1.70 M
$3.34 M-$8.66 M

Analysts recommendations

Institutional Ownership

CUE Latest News

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates
zacks.com14 November 2024 Sentiment: POSITIVE

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.

Cue Biopharma Announces Strategic Organizational Transition
globenewswire.com14 November 2024 Sentiment: POSITIVE

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer (CDO) effective November 25, 2024. Dr. Anish Suri will transition from his current role of president & chief scientific officer (CSO) and will serve the company as principal research and immunology advisor effective as of the same date.

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
globenewswire.com08 November 2024 Sentiment: POSITIVE

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today presented updated data from its Phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the Immuno-STAT™ CUE-100 series, CUE-101, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data was presented in an oral session at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) being held in Houston, Texas and virtually November 6-10.

Cue Biopharma Announces Pricing of $12.0 Million Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 12,435,599 shares of common stock and accompanying common stock warrants to purchase an aggregate of 3,108,900 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.50, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.499. The aggregate gross proceeds of the offering are expected to be approximately $12.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.50 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about September 30, 2024, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
globenewswire.com09 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO).

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript
seekingalpha.com19 August 2024 Sentiment: NEUTRAL

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Ren Benjamin - Citizens JMP Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Edward Tenthoff - Piper Sandler Operator Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com19 August 2024 Sentiment: POSITIVE

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research15 April 2024 Sentiment: POSITIVE

Cue Biopharma (CUE) has identified a hammer chart pattern, suggesting that the stock has found support following a recent decline in value. This, along with an increase in earnings estimate revisions, could signal a potential turnaround for the stock in the near future.

What type of business is Cue Biopharma?

Cue Biopharma Inc is a biopharmaceutical company working in the clinical stage. It is developing a new patented class of biological drugs for selective modulation of the human immune system to treat a wide range of cancers and autoimmune diseases. Its lead drug candidate includes CUE-101, a variant form of interleukin-2 cytokine and T-cell antigen for targeting and activating cancer-specific T cells associated with HPV-related cancer. Other products in development include CUE-102, CUE-103, CUE-400, and CUE-401. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

What sector is Cue Biopharma in?

Cue Biopharma is in the Healthcare sector

What industry is Cue Biopharma in?

Cue Biopharma is in the Biotechnology industry

What country is Cue Biopharma from?

Cue Biopharma is headquartered in United States

When did Cue Biopharma go public?

Cue Biopharma initial public offering (IPO) was on 02 January 2018

What is Cue Biopharma website?

https://www.cuebiopharma.com

Is Cue Biopharma in the S&P 500?

No, Cue Biopharma is not included in the S&P 500 index

Is Cue Biopharma in the NASDAQ 100?

No, Cue Biopharma is not included in the NASDAQ 100 index

Is Cue Biopharma in the Dow Jones?

No, Cue Biopharma is not included in the Dow Jones index

When was Cue Biopharma the previous earnings report?

No data

When does Cue Biopharma earnings report?

The next expected earnings date for Cue Biopharma is 08 April 2025